Study on the Safety and Effectiveness of ALLO-501A CAR T Cells for Adults with Relapsed or Hard-to-Treat Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, and Small Lymphocytic Lymphoma

Inclusion Criteria

For participants with Large B-Cell Lymphoma (LBCL):

• Confirmed diagnosis of relapsed or hard-to-treat large B-cell lymphoma.
• At least one tumor that can be measured at the time of joining the study.
• Cancer has returned or not responded after at least two rounds of chemotherapy.
• No significant antibodies against the treatment product (only for Phase 2).

For participants with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):

• Diagnosis of CLL or SLL.
• Cancer has returned or not responded to treatment.
• Cancer has not responded to BTK inhibitor therapy and is considered high-risk.
• Cancer has not responded after two or more treatments, including BTK inhibitors and BCL-2 inhibitors like venetoclax.
• At least one tumor that can be measured at the time of joining the study.

For all participants:

• Must be 18 years or older.
• Must be in good general health with an ECOG performance status of 0 or 1.
• Must have adequate blood, kidney, and liver function.

Exclusion Criteria

• Active cancer involvement in the brain or spinal cord.
• Current thyroid disorder, unless it is hypothyroidism controlled with medication.
• Any other active cancers that needed treatment in the last 3 years.
• Radiation therapy within 2 weeks before receiving ALLO-647.
• Previous radiation to more than 25% of the bone marrow.
• Low bone marrow cell count for age, based on a biopsy at screening (only for Phase 2).
• Stem cell transplant within the last 6 months.
• Anti-cancer treatment within 2 weeks before receiving ALLO-647.